Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
26.95
+0.67 (2.55%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Braveheart Bio Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Braveheart Bio stock has a consensus rating of "Strong Buy" and an average price target of $44.33. The average 1-year stock price forecast is 64.49% higher than the current stock price, while the lowest is $40 (+48.42%) and the highest is $48 (+78.11%).

Price Target: $44.33 (+64.49%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$40$44.33$45$48
Change+48.42%+64.49%+66.98%+78.11%

Analyst Ratings

The average analyst rating for Braveheart Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingAug '26
Strong Buy4
Buy0
Hold0
Sell0
Strong Sell0
Total4

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiates
$40
BuyInitiates$40+48.42%Aug 31, 2026
TD Cowen
TD Cowen
Buy
Initiates
n/a
BuyInitiatesn/an/aAug 31, 2026
Jefferies
Jefferies
Buy
Initiates
$48
BuyInitiates$48+78.11%Aug 31, 2026
Stifel Nicolaus
Stifel Nicolaus
Buy
Initiates
$45
BuyInitiates$45+66.98%Aug 31, 2026
Goldman Sachs
Goldman Sachs
Buy
Initiates
$48
BuyInitiates$48+78.11%Aug 31, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.44
EPS Next Year
-2.17
from -1.44
Fiscal YearFY 2025FY 2026
Period EndingDec 31, 2025Dec 31, 2026
Revenue
--
Operating Income
-4.51M-98.50M
EPS
--1.44
No. Analysts
-1
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.44
Avg-1.44
Low-1.44

EPS Growth

EPS Growth20272028
High-
Avg-
Low-